Journal of Viral Hepatitis最新文献

{"title":"Trends in Hepatitis B, Hepatitis C, and HIV Seroprevalence in the Netherlands: Insights From Two Decades of Nationwide PIENTER Serosurveys","authors":"Christine G. J. I. van Straten,&nbsp;Birgit H. B. van Benthem,&nbsp;Fiona R. M. van der Klis,&nbsp;Gaby Smits,&nbsp;Eric R. A. Vos,&nbsp;Tom Woudenberg,&nbsp;Marc van der Valk,&nbsp;Eline L. M. Op de Coul","doi":"10.1111/jvh.70213","DOIUrl":"https://doi.org/10.1111/jvh.70213","url":null,"abstract":"<p>Hepatitis B (HBV), hepatitis C (HCV), and HIV remain public health challenges despite effective treatments and preventive options. Infections are often asymptomatic, leading to undiagnosed cases, onward transmission, and preventable morbidity and mortality. In the Netherlands, disease burden is concentrated in specific populations, with many undetected infections. We estimated HBV, HCV, and HIV seroprevalence, identified determinants, and assessed trends over 20 years using data from 14,444 participants aged 15–79 years from three nationwide cross-sectional serosurveys (PIENTER: 1995–1996, 2006–2007, and 2016–2017). Participants completed questionnaires on demographics, behaviour, and socio-economic factors, and serum samples were tested for HBV and HCV in all rounds and HIV in 2017. Seroprevalence estimates were weighted to the Dutch population, trends were analysed using weighted Poisson regression, and determinants were evaluated using multivariable Poisson regression. Weighted HBV seroprevalence remained stable across surveys (3%–5% past or present infection; &lt; 0.4% active infection). HBV prevalence was highest among first-generation migrants, with older age, migration background, and STI history as key determinants. HCV seroprevalence remained low (&lt; 0.4%) and was highest among non-Western migrants. HIV prevalence was 0.1% and highest among non-Western migrants and men who have sex with men. Only 9% of active HBV cases were aware of their status. Overall, HBV, HCV, and HIV seroprevalence remain low in the Netherlands but are concentrated in specific groups with limited awareness. These findings support targeted prevention, screening, and linkage-to-care strategies to achieve the 2030 WHO elimination goals and highlight the importance of continued population-based (sero-)monitoring to guide public health policy.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 8","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70213","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148467558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nationwide Socioeconomic Evaluation of Direct-Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023","authors":"Maito Suoh,&nbsp;Saeed Esmaili,&nbsp;Mohammed Eslam,&nbsp;Jacob George","doi":"10.1111/jvh.70206","DOIUrl":"10.1111/jvh.70206","url":null,"abstract":"<div>\u0000 \u0000 <p>Interferon-free direct-acting antivirals (DAAs), which are highly effective in eliminating hepatitis C virus (HCV), became available in Japan in 2014. This study aimed to estimate the nationwide socioeconomic outcomes of DAA therapy in Japan using publicly available records, including data from the hepatitis subsidy program and universal healthcare claims between fiscal years 2014 and 2023. Based on the standard dose of each DAA regimen, approximately 300,000 people were estimated to have been treated with DAA therapy by 2023, with a cumulative drug cost of at least 1.23 trillion Japanese yen (10.8 billion United States dollars). The main indication for DAA therapy was the initial treatment of chronic HCV infection without cirrhosis. The estimated cost and number of treated people peaked in 2015, followed by a declining trend. For most DAA regimens, annual prescriptions were the greatest in the same or the following year of approval. Sofosbuvir/ledipasvir and glecaprevir/pibrentasvir were the two most common regimens. The age of people treated with DAA therapy shifted towards younger people during the survey period, particularly in males. While the estimated prevalence of people treated with DAA therapy was higher in Western Japan, the estimated number of treated people and population in each prefecture showed a linear association (<i>p</i> &lt; 0.001). Despite the large economic impact, the rapid uptake of DAA therapy suggests an active program of case finding and treatment with the goal of HCV elimination in Japan. Whereas the demographics of people receiving DAA therapy changed over time, treatments were provided uniformly across the nation.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 8","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148456094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Droplet Digital PCR Measurement of HBV DNA in On-Treatment Chronic HBV Patients: Association With HCC Development and Outcomes","authors":"Rex Wan-Hin Hui,&nbsp;Danny Ka-Ho Wong,&nbsp;James Fung,&nbsp;Ka-Shing Cheung,&nbsp;Wai-Kay Seto,&nbsp;Lung-Yi Mak,&nbsp;Man-Fung Yuen","doi":"10.1111/jvh.70209","DOIUrl":"10.1111/jvh.70209","url":null,"abstract":"<div>\u0000 \u0000 <p>Low-level residual viremia can be present in chronic hepatitis B (CHB) patients on nucleos(t)ide analogues (NUCs). Due to the detection limits of current HBV DNA assays, the association between residual viremia and HBV-related HCC has not been well studied. This study included NUC-treated HBV-related HCC patients with unquantifiable serum HBV DNA by the conventional Cobas-Taqman assay (&lt; 20 IU/mL) at HCC diagnosis. The HCC patients were matched in a 1:1 ratio with NUC-treated non-HCC controls. Serum samples at the time of HCC diagnosis, 1 year before, and 2 years before diagnosis were retrospectively retrieved and tested for residual viremia by a validated high-sensitivity droplet digital polymerase chain reaction assay (lower limit of detection 1.6 IU/mL). Among 208 patients (104 HCC vs. 104 controls; mean age 63.1, 80.8% male, 54.3% cirrhosis), residual viremia within 2 years was observed in 82.7% of HCC patients and 49.0% of controls (<i>p</i> &lt; 0.001), and was independently associated with HCC occurrence (OR 7.243, 95% CI 1.862–28.170, <i>p</i> = 0.004). In HCC patients, residual viremia was associated with histological microvascular invasion (44.4% vs. 9.1% in patients without residual viremia, <i>p</i> = 0.033) and lower probability of presenting with Barcelona Clinic Liver Cancer stage 0 HCC (OR 0.281, 95% CI 0.094–0.838, <i>p</i> = 0.023). After median follow-up for 7.2 years, residual viremia within 2 years before HCC diagnosis was independently associated with liver-related mortality (HR 4.472, 95% CI 1.212–16.504, <i>p</i> = 0.025). Residual viremia in NUC-treated CHB patients is associated with a higher risk of HCC development, more advanced tumour staging and poorer outcomes. High-sensitivity HBV DNA assays may be utilized for monitoring in NUC treatment.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 8","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148436989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Mortality After the Roll-Out of Directly Acting Antivirals for Hepatitis C in England Using Linked Surveillance Data","authors":"David Etoori,&nbsp;Ruth Simmons,&nbsp;Annabel Powell,&nbsp;Monica Desai,&nbsp;Paul Trembling,&nbsp;Caroline Sabin,&nbsp;William Rosenberg","doi":"10.1111/jvh.70210","DOIUrl":"10.1111/jvh.70210","url":null,"abstract":"<p>Directly acting antivirals (DAAs) revolutionised hepatitis C virus (HCV) treatment, offering higher cure rates. We aimed to quantify life expectancy (LE) differences between treated and untreated individuals diagnosed with HCV and assess the contributions of age and causes of death to these differences. We used routine HCV surveillance data linked with UK mortality records. Individuals contributed person-time from age 15 or the earliest HCV diagnosis, whichever was later, and were classified as treated six months post-treatment initiation. The study was divided into two periods: 2015–2018 (Period 1), representing early DAA roll-out targeting advanced liver disease, and 2019–2022 (Period 2). We used non-parametric survival analysis methods and mortality decomposition methods to estimate LE differences, and age- and cause-specific contributions to LE differences. A total of 92,920 individuals contributed 322,570 untreated and 200,581 treated person-years of observation, and 13,294 deaths to the analyses. In Period 1, there was an 8.5-year LE advantage at age 15 for treated females (95% CI: 5.4–11.5) and 8.9 years for treated males (95% CI: 5.6–12.2). In Period 2, this declined to 6.7 (95% CI: 3.3–10.2) and 5.3 (95% CI: 3.0–7.6), respectively. The narrowing gap was driven by rising deaths from suicide, alcohol, and drug misuse in the treated population and corresponding declines in the untreated population. Treated individuals with HCV had consistently higher LE, though the advantage decreased over time. We hypothesise that the early prioritisation of individuals with cirrhosis resulted in a relatively healthier untreated population (i.e., fewer cirrhotic cases) in the later period.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 8","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70210","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Studies of Infectious Disease Elimination (InSIDE): Hepatitis C Antibody and RNA Status of Persons Who Inject Drugs in New York State, 2021–2023","authors":"Meredith A. Barranco,&nbsp;Sarah Shufelt,&nbsp;Colleen Flanigan,&nbsp;Larissa Wilberschied,&nbsp;Tomoko Udo","doi":"10.1111/jvh.70208","DOIUrl":"10.1111/jvh.70208","url":null,"abstract":"<div>\u0000 \u0000 <p>Hepatitis C virus (HCV) infection disproportionately impacts people who inject drugs (PWID). Understanding the prevalence and correlates of current and lifetime HCV infection is necessary to inform prevention, testing and treatment efforts among PWID to reduce HCV burden and achieve HCV elimination targets in this population From June 2021–December 2023, 751 PWID were recruited from syringe service harm reduction programs (SSP) and by referral from communities around New York State (NYS). Participants completed web-based surveys on risk factors and social determinants of health and were tested for HCV antibody and RNA to assess their current and lifetime HCV status (never infected, previously infected, or currently infected). Controlling for recruitment site as a fixed effect, a multivariate mixed logistic regression model was built to assess factors significantly associated with HCV status. Among PWID, 58% had a lifetime history of infection, and 29% were currently infected (50% among those with a lifetime history of infection). Daily/almost-daily injection, opioid injection, homelessness, and experience of abscess (all past-year) were significantly associated with current infection, as was younger age. Past-year SSP utilization was associated with a lifetime history of infection. PWID are a priority population to achieve HCV elimination in NYS. Our findings show that HCV burden is high among PWID utilizing SSPs. Expanding access to HCV care and treatment in harm reduction service settings while also providing services to address social determinants of health may be an effective strategy to progress towards reducing the burden of HCV among PWID.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 8","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148422197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Patterns of Chronic Hepatitis B Care and Treatment Adherence in Australia: A National Linked Data Cohort Study","authors":"Jennifer H. MacLachlan,&nbsp;Nicole Romero,&nbsp;Stacey L. Rowe,&nbsp;Nicole Allard,&nbsp;Benjamin C. Cowie","doi":"10.1111/jvh.70207","DOIUrl":"10.1111/jvh.70207","url":null,"abstract":"<p>Current uptake of chronic hepatitis B (CHB) treatment and care in Australia is well below target levels, leading to an ongoing burden of preventable liver disease and cancer. Understanding individual-level trajectories of care engagement and variation by sociodemographic factors is essential to guide efforts to improve access to and retention in care. This study analysed records of hepatitis B viral load (VL) testing and antiviral treatment provided through Australia's national health insurance system, which were linked to migration, death, and sociodemographic data from various government datasets. Treatment and VL testing by population group were assessed, and uptake was calculated using modelled estimates of the number living with CHB. VL testing frequency and treatment adherence based on scripts dispensed were also assessed. Of the estimated 219,800 people living with CHB in Australia in 2023, 118,334 (53.8%) received either VL testing or treatment during 2014–2023. Estimated uptake of VL testing and treatment uptake were lower among Aboriginal and Torres Strait Islander people and also varied by region of birth. Of the 81,360 who received any VL testing, only 17,352 (21.3%) received it regularly, while 31,715 (39.0%) had evidence of prior monitoring but no VL testing since 2019. The majority of those who initiated treatment continued therapy and received supply sufficient for adherence. This study shows that substantial gaps exist in CHB care in Australia, particularly in continued monitoring among those not on treatment. Disparities in uptake are evident by priority population. Re-engaging those lost to follow-up should be prioritised.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 8","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70207","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148412202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatocellular Carcinoma Risk Between Untreated Immune Tolerant Vs. Treated Immune Active Chronic Hepatitis B Patients","authors":"Robert J. Wong,&nbsp;Zeyuan Yang,&nbsp;Ramsey Cheung","doi":"10.1111/jvh.70204","DOIUrl":"10.1111/jvh.70204","url":null,"abstract":"<div>\u0000 \u0000 <p>The risk of hepatocellular carcinoma (HCC) between chronic hepatitis B (CHB) patients in the untreated immune tolerant (U-IT) vs. treated immune active (T-IA) phases is not clear, and most data are in Asian populations. We aim to evaluate long-term risks of cirrhosis, HCC, and overall mortality between U-IT vs. T-IA CHB patients among a national cohort of U.S. Veterans. We conducted a propensity score weighted analysis of Veterans with CHB who met criteria for U-IT or T-IA from 1/1/2010 to 12/31/2021 (with follow-up through 12/31/2024). Incidence of cirrhosis, HCC, or death were compared between U-IT and T-IA groups. A total of 591 U-IT and 555 T-IA CHB patients were identified (mean age 56.4–57.5 years, 45%–50% non-Hispanic white, 37%–40% African American, 9%–10% Asian, 25%–29% concurrent diabetes, 35%–39% with FIB-4 &gt; 3.25). Over a median follow up of 6.4 years (IQR 3.0–10.4), incidence of HCC was significantly lower in U-IT patients vs. T-IA patients (0.28 vs. 0.54 per 100 person-years; HR 0.52, 95% CI 0.32–0.83, <i>p</i> = 0.007). However, the risk of cirrhosis or all-cause mortality was similar between both T-IA and U-IT CHB patients. Among a predominantly non-Asian cohort of adults with CHB, we observed that HCC risk was lower in U-IT patients compared to T-IA patients. While this contrasts with some studies in Asian countries, these data do emphasize the importance of prioritizing and ensuring timely therapy for CHB patients in the IA phase. However, routine treatment in IT patients remains controversial and more data are needed to better understand long-term outcomes.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 8","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148397058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring of the Cascade of Care in Patients With Chronic HBV in Primary Care Clinics in Australia","authors":"Dina Moussa,&nbsp;Jack Wallace,&nbsp;Jacqui Richmond,&nbsp;Joseph S. Doyle,&nbsp;Long Nguyen,&nbsp;Douglas Boyle,&nbsp;Mark A. Stoové,&nbsp;Jason Asselin,&nbsp;Victoria Polkinghorne,&nbsp;Marvad Ahad,&nbsp;Susanne Glasgow,&nbsp;Kate New,&nbsp;Lena Sanci,&nbsp;Matt Penn,&nbsp;John Furler,&nbsp;Alexander Thompson,&nbsp;Margaret Hellard,&nbsp;Jess Howell","doi":"10.1111/jvh.70203","DOIUrl":"https://doi.org/10.1111/jvh.70203","url":null,"abstract":"<p>To achieve hepatitis B virus (HBV) elimination in Australia, a shift from hospital to community-based care is needed. This study aimed to describe the prevalence of chronic HBV and uptake of the cascade of care in primary care patients. This prospective cohort study was conducted in 76 urban and regional primary care clinics across Victoria, Australia between 1/7/2020 and 30/6/2023. Anonymised socio-demographic, clinical and laboratory data from general practice (GP) clinics' electronic medical records (EMR) were extracted. Descriptive analysis of the cohort of clinic clients with HBV was performed. A total of 346,927 individuals attended appointments across the study period. Of these, 25,212 had records indicating HBV-related testing. 491 (0.14%) individuals had evidence of current HBV infection defined as HBV surface antigen (HBsAg) positive and/or HBV DNA positive. 469 attended the clinics during the study period, among whom 239 (51%) were female. In the GP EMR, only 59 (13%) had evidence of at least one HBV DNA test and at least one ALT test ordered. Fourteen patients (3%) had record of being reviewed for HBV management by the clinic nurse or GP and 78 (17%) reviewed by a viral hepatitis specialist. Ninety-two (20%) were on treatment for HBV. Of people receiving treatment, 23 (25%) had a record of linkage to specialist care. Our data show that significant gaps in the cascade of care remain for people with chronic HBV in primary care settings, with a low proportion of patients having evidence of participating in all stages of the HBV cascade of care.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 8","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70203","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148389182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HERACLIS_BLV_D: Adherence to Real-Life Therapy With Bulevirtide in Chronic Hepatitis D","authors":"Dimitra Lakiotaki,&nbsp;Margarita Papatheodoridi,&nbsp;Vasilios Sevastianos,&nbsp;Kalliopi Zachou,&nbsp;Dimitrios Christodoulou,&nbsp;John Koskinas,&nbsp;Melanie Deutsch,&nbsp;Alexandra Alexopoulou,&nbsp;Ioannis Elefsiniotis,&nbsp;Christos Triantos,&nbsp;Elena Gigi,&nbsp;Theodoros Androutsakos,&nbsp;Dimitrios S. Karagiannakis,&nbsp;Iliana Mani,&nbsp;Dimitrios Dimitroulopoulos,&nbsp;Maria Mela,&nbsp;Emmanouil Sinakos,&nbsp;Spyros Michopoulos,&nbsp;Konstantinos Mimidis,&nbsp;Nikolaos Papadopoulos,&nbsp;Athanasios Kontos,&nbsp;Christos Veretanos,&nbsp;Dimitrios Lymperopoulos,&nbsp;George Giannoulis,&nbsp;Vasilios Papadimitropoulos,&nbsp;Evdoxia Avramopoulou,&nbsp;Alkistis Papatheodoridi,&nbsp;Spyridon Pantzios,&nbsp;Larisa Vasilieva,&nbsp;Hariklia Kranidioti,&nbsp;Emmanouil Koullias,&nbsp;Athanasios Soukovelos,&nbsp;Paraskevi Fytili,&nbsp;John Vlachogiannakos,&nbsp;Evangelos Cholongitas,&nbsp;Spilios Manolakopoulos,&nbsp;Ioannis Goulis,&nbsp;George Dalekos,&nbsp;George Papatheodoridis","doi":"10.1111/jvh.70201","DOIUrl":"https://doi.org/10.1111/jvh.70201","url":null,"abstract":"<p>Daily subcutaneous bulevirtide (BLV) 2 mg has been approved as first-line treatment for chronic hepatitis D (CHD), but long-term real-world adherence data are limited. We assessed adherence rates during BLV therapy and their impact on treatment response. HERACLIS_BLV_D study (NCT05928000) included adult CHD patients initiating BLV 2 mg/day and followed in routine clinical practice. Virological response (VR) was defined as HDV RNA &lt; 57.5 IU/mL or decline &gt; 2 log₁₀ and biochemical response (BR) as normal ALT (≤ 40 IU/L). Adherence was evaluated through the national prescription system based on executed monthly BLV prescriptions. Treatment discontinuation was defined as no executed BLV prescription for &gt; 3 months at the end of follow-up. Seventy-six patients were included. VR/BR rates were 73%/71% at 12 and 93%/74% at 24 months. Thirteen (17%) patients discontinued BLV (none due to adverse events); 6%–7% per year. Mean adherence among treated patients was 98% ± 6% in 1st year declining to 93% ± 13% in 2nd and 91% ± 17% in 3rd year (<i>p</i> ≤ 0.010). No baseline characteristic was associated with poor (&lt; 90%) or good (≥ 90%) adherence to BLV therapy. Patients with poor vs. good adherence had lower VR rates (1st year: 33% vs. 77%, <i>p</i> = 0.038; 2nd year: 60% vs. 97%, <i>p</i> = 0.030). In conclusion, in clinical practice, &lt; 10% of CHD patients discontinue BLV therapy annually. Adherence is excellent in the first year and remains &gt; 90% until the third year although gradually declines. Poor (&lt; 90%) adherence cannot be predicted but adversely affects the VR rates emphasizing the need for strategies to support long-term treatment retention.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 7","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70201","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148282429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Utility of Shortened Read Time of the Abbott Bioline HCV Test to Predict Viremia","authors":"Bridget Louise Draper,&nbsp;Mon Mon Su Naing,&nbsp;Hla Htay,&nbsp;Mia Flynn,&nbsp;Mark Stoove,&nbsp;Margaret Hellard,&nbsp;Alisa Pedrana","doi":"10.1111/jvh.70198","DOIUrl":"10.1111/jvh.70198","url":null,"abstract":"<p>The current two-step model for HCV diagnosis risks losing people from care; a one-step diagnostic approach could improve retention. We investigated whether shortening the read time of an HCV antibody test from 20-min to 1 or 5-min could accurately predict HCV RNA viremia in-lieu of a standard RNA test. 1110 people in Yangon had a HCV Ab using Bioline HCV RDT. Results were recorded at 1-min intervals until 20-min, with HCV RNA testing of reactive results at 20-min. 884 participants returned both antibody and RNA results; 838 were Ab reactive at 1-min, 875 were reactive at 5-min and 728 were RNA positive. Sensitivity was 98.6% and 100% for 1 and 5-min read-times, and specificity was 23.1% and 5.8% for 1 and 5-min respectively. Our results suggest that reading the Bioline at 5 min has potential to identify patients with HCV infection ahead of reflexive RNA testing.</p><p><b>Trial Registration:</b> ClinicalTrials.gov:NCT03939013</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 7","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70198","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148265172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}